126 related articles for article (PubMed ID: 9308077)
21. Monitoring interstitial m-THPC-PDT in vivo using fluorescence and reflectance spectroscopy.
Kruijt B; van der Ploeg-van den Heuvel A; de Bruijn HS; Sterenborg HJ; Amelink A; Robinson DJ
Lasers Surg Med; 2009 Nov; 41(9):653-64. PubMed ID: 19802884
[TBL] [Abstract][Full Text] [Related]
22. In vivo measurement of 5-aminolaevulinic acid-induced protoporphyrin IX photobleaching: a comparison of red and blue light of various intensities.
Nadeau V; O'Dwyer M; Hamdan K; Tait I; Padgett M
Photodermatol Photoimmunol Photomed; 2004 Aug; 20(4):170-4. PubMed ID: 15238094
[TBL] [Abstract][Full Text] [Related]
23. PDT dose dosimetry for Photofrin-mediated pleural photodynamic therapy (pPDT).
Ong YH; Kim MM; Finlay JC; Dimofte A; Singhal S; Glatstein E; Cengel KA; Zhu TC
Phys Med Biol; 2017 Dec; 63(1):015031. PubMed ID: 29106380
[TBL] [Abstract][Full Text] [Related]
24. In vivo fluorescence kinetics and photodynamic therapy in condylomata acuminata.
Stefanaki IM; Georgiou S; Themelis GC; Vazgiouraki EM; Tosca AD
Br J Dermatol; 2003 Nov; 149(5):972-6. PubMed ID: 14632801
[TBL] [Abstract][Full Text] [Related]
25. Low-fluence rate, long duration photodynamic therapy in glioma mouse model using organic light emitting diode (OLED).
Guo HW; Lin LT; Chen PH; Ho MH; Huang WT; Lee YJ; Chiou SH; Hsieh YS; Dong CY; Wang HW
Photodiagnosis Photodyn Ther; 2015 Sep; 12(3):504-10. PubMed ID: 25936596
[TBL] [Abstract][Full Text] [Related]
26. Relationship of protoporphyrin IX synthesis to photodynamic effects by 5-aminolaevulinic acid and its esters on various cell lines derived from the skin.
Lee JB; Choi JY; Chun JS; Yun SJ; Lee SC; Oh J; Park HR
Br J Dermatol; 2008 Jul; 159(1):61-7. PubMed ID: 18489589
[TBL] [Abstract][Full Text] [Related]
27. A quantitative comparison of 5-aminolaevulinic acid- and methyl aminolevulinate-induced fluorescence, photobleaching and pain during photodynamic therapy.
Valentine RM; Ibbotson SH; Brown CT; Wood K; Moseley H
Photochem Photobiol; 2011; 87(1):242-9. PubMed ID: 21077899
[TBL] [Abstract][Full Text] [Related]
28. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.
Tyrrell JS; Campbell SM; Curnow A
Lasers Surg Med; 2010 Sep; 42(7):613-9. PubMed ID: 20806386
[TBL] [Abstract][Full Text] [Related]
29. Fractionated illumination at low fluence rate photodynamic therapy in mice.
Middelburg TA; Van Zaane F; De Bruijn HS; Van Der Ploeg-van den Heuvel A; Sterenborg HJ; Neumann HA; De Haas ER; Robinson DJ
Photochem Photobiol; 2010; 86(5):1140-6. PubMed ID: 20553407
[TBL] [Abstract][Full Text] [Related]
30. Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy.
Ascencio M; Collinet P; Farine MO; Mordon S
Lasers Surg Med; 2008 Jul; 40(5):332-41. PubMed ID: 18563777
[TBL] [Abstract][Full Text] [Related]
31. Monitoring PDT by means of superficial reflectance spectroscopy.
Amelink A; van der Ploeg van den Heuvel A; de Wolf WJ; Robinson DJ; Sterenborg HJ
J Photochem Photobiol B; 2005 Jun; 79(3):243-51. PubMed ID: 15896651
[TBL] [Abstract][Full Text] [Related]
32. Tumor reactive ringlet oxygen approach for Monte Carlo modeling of photodynamic therapy dosimetry.
Lopez N; Mulet R; Rodríguez R
J Photochem Photobiol B; 2016 Jul; 160():383-91. PubMed ID: 27197059
[TBL] [Abstract][Full Text] [Related]
33. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.
Ericson MB; Sandberg C; Stenquist B; Gudmundson F; Karlsson M; Ros AM; Rosén A; Larkö O; Wennberg AM; Rosdahl I
Br J Dermatol; 2004 Dec; 151(6):1204-12. PubMed ID: 15606516
[TBL] [Abstract][Full Text] [Related]
34. Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy.
Tyrrell J; Campbell S; Curnow A
Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):232-8. PubMed ID: 21112545
[TBL] [Abstract][Full Text] [Related]
35. Photodynamic effectiveness and vasoconstriction in hairless mouse skin after topical 5-aminolevulinic acid and single- or two-fold illumination.
van der Veen N; Hebeda KM; de Bruijn HS; Star WM
Photochem Photobiol; 1999 Dec; 70(6):921-9. PubMed ID: 10628304
[TBL] [Abstract][Full Text] [Related]
36. A study of concentration changes of Protoporphyrin IX and Coproporphyrin III in mixed samples mimicking conditions inside cancer cells for Photodynamic Therapy.
Landes R; Illanes A; Goeppner D; Gollnick H; Friebe M
PLoS One; 2018; 13(8):e0202349. PubMed ID: 30169536
[TBL] [Abstract][Full Text] [Related]
37. Light dosimetry in vivo.
Star WM
Phys Med Biol; 1997 May; 42(5):763-87. PubMed ID: 9172258
[TBL] [Abstract][Full Text] [Related]
38. The effect of light fractionation with a 2-h dark interval on the efficacy of topical hexyl-aminolevulinate photodynamic therapy in normal mouse skin.
Middelburg TA; de Bruijn HS; van der Ploeg-van den Heuvel A; Neumann HA; Robinson DJ
Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):703-9. PubMed ID: 24284130
[TBL] [Abstract][Full Text] [Related]
39. Evidence for a bystander role of neutrophils in the response to systemic 5-aminolevulinic acid-based photodynamic therapy.
de Bruijn HS; Sluiter W; van der Ploeg-van den Heuvel A; Sterenborg HJ; Robinson DJ
Photodermatol Photoimmunol Photomed; 2006 Oct; 22(5):238-46. PubMed ID: 16948825
[TBL] [Abstract][Full Text] [Related]
40. Targeting of sebaceous glands by δ-aminolevulinic acid-based photodynamic therapy: An in vivo study.
Kosaka S; Miyoshi N; Akilov OE; Hasan T; Kawana S
Lasers Surg Med; 2011 Jul; 43(5):376-81. PubMed ID: 21674542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
